SAVE ENERGY – Charging Mobile at Night is a National Waste.

SAVE ENERGY – Charging Mobile at Night is a National Waste We have habit of keeping mobile for charging at night. After 2 hours of charging the mobile is fully charged and for the rest part of night it is connected without any purpose.  As per a recent study approximately 4 watts are consumed during this time. It looks insignificant ... Read More »

UniQure’s gene therapy increases clotting in some hemophilia B patients

UniQure’s gene therapy increases clotting in some hemophilia B patients UniQure said preliminary results from the low-dose cohort in a phase I/II clinical trial assessing its AAV5/FIX gene therapy, AMT-060, in patients with moderately severe to severe hemophilia B demonstrated a significant clinical benefit in two participants. The company said all five patients in the low-dose cohort had Factor IX ... Read More »

Glenmark receives tentative US FDA approval for generic Multaq tablets

Glenmark receives tentative US FDA approval for generic Multaq tablets Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted tentative approval by the United States Food & Drug Administration (US FDA) for its dronedarone tablets, 400 mg, the generic version of Multaq tablets, 400 mg of Sanofi-Aventis US, LLC. ‘Tentative approval’ means that FDA has concluded that a drug product has ... Read More »

Be thankful to smallest favors….

Be thankful to smallest favors Air Commodore Vishal was a Jet Pilot. In a combat mission his fighter plane was destroyed by a missile. He however ejected himself and parachuted safely. He won acclaims and appreciations from many. After five years one day he was sitting with his wife in a restaurant. A man from another table came to him ... Read More »

SMS Pharma rises 12% on USFDA nod for Andhra Pradesh plant

SMS Pharma rises 12% on USFDA nod for Andhra Pradesh plant Shares of SMS Pharmaceuticals  climbed 11.8 percent in early trade Monday on getting approval from the US health regulator for one of its unit in Andhra Pradesh. “SMS has received approval from the US Food and Drug Administration (USFDA) for manufacturing facility (unit 7) located at Kandivalasa village, Pusapatirega ... Read More »

Indian pharma market crosses Rs 1,00,000 crore mark: IMS Health

Indian pharma market crosses Rs 1,00,000 crore mark: IMS Health  MUMBAI: The Indian pharmaceutical market has for the first time crossed the Rs 100000 crore mark in November when calculated on the basis of Moving Annual Total (MAT), said IMS Health, a global pharmaceutical market research firm. In its monthly review of the local market, IMS Health said in its ... Read More »

FDA approves Wellstat’s Vistogard for chemotherapy overdose

FDA approves Wellstat’s Vistogard for chemotherapy overdose The US Food and Drug Administration (FDA) has approved Wellstat Therapeutics’ Vistogard (uridine triacetate) to treat overdose of fluorouracil or capecitabine, which are administered for several malignancies. Vistogard is claimed to be the first antidote for emergency treatment of 5-fluorouracil (5-FU) overdose treatment available to patients. It is also indicated for patients exhibiting ... Read More »

The Stone Cutter

                       The Stone Cutter   Once upon a time there lived a stone cutter ,in a small village. All day long he worked hard, cutting the hard stones and making the shape which were needed by his customers. His hands were hard and his clothes were dirty. One day he ... Read More »

Bial’s Zebinix meets primary endpoint in phase 3 study for patients with newly diagnosed partial-onset seizures

Bial’s Zebinix meets primary endpoint in phase 3 study for patients with newly diagnosed partial-onset seizures Bial has unveiled positive results for a pivotal phase 3 non-inferiority study comparing the efficacy and safety of eslicarbazepine acetate (ESL) to controlled release carbamazepine (CBZ-CR) as monotherapy in newly diagnosed adult patients with partial-onset seizures (POS). Bial director of research & development department ... Read More »

Can Pfizer finally orchestrate a winning megamerger after so many disappointments?

Can Pfizer finally orchestrate a winning megamerger after so many disappointments? Pfizer’s ($PFE) decision to buy Allergan ($AGN) wasn’t much of a surprise; the nominally Dublin-based Allergan was among the few buyout targets that could deliver CEO Ian Read‘s desired tax inversion. Nor is it surprising that Pfizer chose to rack up another megamerger, given its history of huge deals. ... Read More »

BIGTheme.net • Free Website Templates - Downlaod Full Themes
Social Media Auto Publish Powered By : XYZScripts.com